Los Angeles Capital Management LLC Lowers Stock Holdings in Insmed, Inc. $INSM

Los Angeles Capital Management LLC cut its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 35.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 82,385 shares of the biopharmaceutical company’s stock after selling 45,118 shares during the period. Los Angeles Capital Management LLC’s holdings in Insmed were worth $14,338,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Havemeyer Place LP purchased a new stake in Insmed during the fourth quarter worth about $1,025,000. Vestcor Inc purchased a new stake in Insmed during the fourth quarter worth about $738,000. Fjarde AP Fonden Fourth Swedish National Pension Fund purchased a new stake in Insmed during the fourth quarter worth about $8,789,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Insmed during the fourth quarter worth about $261,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in Insmed during the fourth quarter worth about $2,011,000.

Analysts Set New Price Targets

A number of brokerages have issued reports on INSM. Jefferies Financial Group began coverage on shares of Insmed in a research note on Monday, March 16th. They set a “buy” rating and a $228.00 price target on the stock. Guggenheim cut their price target on shares of Insmed from $230.00 to $226.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Wells Fargo & Company cut their price target on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. HC Wainwright reiterated a “buy” rating on shares of Insmed in a research note on Friday, May 8th. Finally, Roth Mkm reiterated a “buy” rating and set a $212.00 price target on shares of Insmed in a research note on Friday, April 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $210.50.

Insiders Place Their Bets

In related news, COO Roger Adsett sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $242,379.90. Following the completion of the sale, the chief operating officer owned 98,603 shares in the company, valued at $10,084,128.81. The trade was a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Sara Bonstein sold 2,404 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the sale, the chief financial officer owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. The trade was a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 160,482 shares of company stock worth $24,438,193 in the last three months. 2.10% of the stock is owned by company insiders.

Insmed Stock Performance

Shares of INSM opened at $94.22 on Monday. The stock has a 50-day simple moving average of $130.45 and a 200-day simple moving average of $154.65. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The stock has a market capitalization of $20.42 billion, a PE ratio of -16.39 and a beta of 0.79. Insmed, Inc. has a 1 year low of $70.57 and a 1 year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. The business had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business’s quarterly revenue was up 229.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.42) EPS. On average, analysts predict that Insmed, Inc. will post -2.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.